Licensing & Partnership Inquiries
Trivalent Therapeutics welcomes inquiries from pharmaceutical companies, investors, and research institutions interested in licensing our patent-protected methods for treating alcohol use disorder, with opioid use disorder as an adjacent, investigational indication. Reach out using the details below and a member of our team will respond promptly.
Patent Reference
When contacting us regarding our intellectual property, please reference U.S. Nonprovisional Utility Patent Application No. 19/705,839 — Methods of Treating Alcohol Use Disorder and Related Conditions Using Retatrutide. The filed method claims also reach opioid use disorder as an adjacent, investigational indication; naltrexone is approved as a single agent there, and the combination is untested.
Ready to Discuss Licensing?
Email our licensing team directly and we'll arrange a conversation about how our alcohol use disorder methods — and their adjacent, investigational reach into opioid use disorder — can support your development program.
Email Licensing Team